Clinical Trials Logo
  1. Home
  2. Primary Hypercholesterolemia
  3. NCT06314919
  4. Details
NCT06314919 Clinical Trial

A Study to Evaluate the Efficacy and Safety of Fixed-Dose Combination of Pitavastatin/Ezetimib

Primary Hypercholesterolemia Clinical Trial

Official title:
A Multicenter, Prospective, Cohort Study to Evaluate the Efficacy and Safety of Fixed-Dose Combination of Pitavastatin/Ezetimibe Under the Real-World Condition

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT06314919
Other study ID # BR-PEC-OS-401
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date March 15, 2024
Est. completion date March 2026

Study information
Verified date April 2024
Source Boryung Pharmaceutical Co., Ltd
Contact Shin-young Oh
Phone +82-2-708-8000
Email syoh@boryung.co.kr
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy and safety of fixed-Dose combination of Pitavastatin/Ezetimibe under the real-world condition

Recruitment information / eligibility
Status Recruiting
Enrollment 8606
Est. completion date March 2026
Est. primary completion date March 2026
Accepts healthy volunteers No
Gender All
Age group 19 Years and older
Eligibility Inclusion Criteria: - Those who taking statins or statins and ezetimibe in addition to dietary and exercise therapy for primary hypercholesterolemia or mixed hyperlipidemia - Those who are judged to need administration of a fixed-dose combination of pitavastatin/ezetimibe for change of statin's formulation or change of statin's dose, addition of ezetimibe Exclusion Criteria: - Those who are taking a fixed-dose combination of pitavastatin/ezetimibe at study enrollment - Those with hypersensitivity reactions or relevant medical history to pitavastatin or ezetimibe - Those who have been administered an investigational product within 12 weeks of the enrollment date or are planning to participate in another clinical trial during this study participation period.

Study Design

Related Conditions & MeSH terms

Locations
Country Name City State
Korea, Republic of Ewha Womans University Seoul Hospital Seoul

Sponsors (1)
Lead Sponsor Collaborator
Boryung Pharmaceutical Co., Ltd

Country where clinical trial is conducted

Korea, Republic of, 

Outcome
Type Measure Description Time frame Safety issue
Primary Rate of reaching the target LDL Cholesterol level 12 weeks after administration
See also
  Status Clinical Trial Phase
Recruiting NCT05559606 - An OS to Evaluate the Safety & Efficacy of Fixed Dose Combination Therapy With Atorvastatin and Ezetimibe
Completed NCT03571087 - Efficacy and Safety of Combination of Rosuvastatin and Ezetimibe in Patients With Primary Hypercholesterolemia Phase 3
Completed NCT00776321 - Eprotirome for the Treatment of Dyslipidemia, Efficacy and Safety 12-Week, Phase ii Study to Assess the Safety and Efficacy of KB2115 in Patients With Primary Hypercholesterolemia Phase 2
Recruiting NCT05399992 - Study Evaluating Effectiveness and Adherence of Inclisiran Plus Standard of Care (SoC) Lipid-lowering Therapy Compared to SoC in ASCVD
Withdrawn NCT05798390 - Treatment With Bempedoic Acid And/Or Its Fixed-dose Combination With Ezetimibe in Routine Clinical Practice in Patients With Primary Hypercholesterolemia Or Mixed Dyslipidemia
Completed NCT00724477 - Retrospective Evaluation of the Percentage of Subjects Who Have Reached Their LDL-C Objectives After Treatment With INEGY (Study P05103)(COMPLETED)
Completed NCT00249249 - Study to Compare the Efficacy of Pitavastatin With That of Atorvastatin in Lowering Cholesterol Levels Phase 3
Recruiting NCT05657574 - A Clinical Trial to Evaluate the Efficacy and Safety of CKD-391 and CKD-331 in Patients With Primary Hypercholesterolemia Phase 3
Completed NCT03516955 - Efficacy and Safety of a Generic Rosuvastatin in a Real-world Setting
Completed NCT02941848 - Evaluate the Pharmacokinetics and Safety of HCP1306 and Co-administration of HGP0816, HGP1404 in Healthy Male Volunteers Phase 1
Completed NCT01012219 - A Study to Evaluate the Effects of Laropiprant on the Antiplatelet Effects of Clopidogrel and Aspirin in Combination (MK-0524A-114)(COMPLETED) Phase 1
Completed NCT05131997 - A Study to Evaluate the Efficacy and Safety of AD-221 and AD-221A Phase 3
Terminated NCT03433755 - Safety and Efficacy of Evolocumab in Addition to Optimal Stable Background Statin Therapy in Chinese Participants With Primary Hypercholesterolemia and Mixed Dyslipidemia Phase 3
Completed NCT00867165 - Pediatric Study to Evaluate the Efficacy and Safety of Ezetimibe Monotherapy in Children With Primary Hypercholesterolemia (P05522) Phase 3
Not yet recruiting NCT06386419 - A Clinical Study to Evaluate the Safety and Effectiveness of Inclisiran Sodium in Indian Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia Phase 4
Active, not recruiting NCT03952169 - Effect of Probiotics on Lipid Management N/A
Terminated NCT01335997 - Efficacy and Safety of Extended-Release Niacin/ Laropiprant/Simvastatin Tablets in Participants With Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-143) Phase 3
Completed NCT02087917 - A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia Phase 2
Completed NCT00704535 - Evaluation of the Safety, Tolerability and Efficacy of Ezetimibe on a Select Population of Filipinos With Hypercholesterolemia (Study P04748)(COMPLETED)
Terminated NCT01274559 - Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels (MK-0524A-133) Phase 3